---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-004143"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:40:01.061773+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Agios unveils 2023-2026 catalysts: PYRUKYND approvals, pipeline expansion, cash-flow positivity by 2026

## Summary
- Five ongoing pivotal PYRUKYND trials in thalassemia, sickle cell, and pediatric PK deficiency.
- Potential FDA approvals: thalassemia 2025, sickle cell 2026, pediatric PK deficiency 2026.
- Expects to complete ENERGIZE/ENERGIZE-T enrollment by mid-2023; RISE UP Phase 2 data and go/no-go by mid-year.
- AG-946 Phase 2a enrollment in LR-MDS completed by year-end 2023; IND filing for PAH stabilizer in PKU planned.
- Appointed Tsveta Milanova as CCO; EU/Great Britain approval for PYRUKYND in adult PK deficiency already received.

## SEC filing metadata
- accession: 0001193125-23-004143
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000119312523004143/0001193125-23-004143-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000119312523004143/d408672d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-004143
- JSON: https://secwatch.observer/filing/0001193125-23-004143.json
- Plain text: https://secwatch.observer/filing/0001193125-23-004143.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.